Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: PCSS who wrote (2088)	4/21/2004 1:22:44 PM
From: tom pope	Respond to of 3044

Michael, I didn't contribute anything, I was just admitting that I often find it challenging to connect Rick and Miljenko's dots.

To: PCSS who wrote (2088)	4/21/2004 2:10:23 PM
From: tuck	Respond to of 3044

PCSS, Even if you don't understand much of the science contained in that Medscape link I posted, it provides a nice picture of the clinical program for combos and monotherapy involving Velcade (albeit a year old). You can see that many of the combos are in PII, so we should get some indicators of efficacy going forward. The colorectal trial that was halted is a small setback, but as Miljenko pointed out, the irinotecan-refractory population for that indication is very difficult for any regimen to show good results in. It was an ambitious trial. I expect better results from most of the other trials. Cheers, Tuck